Table of Contents

ACTIV-6

ACTIV-6, officially ACTIV-6: COVID-19 Outpatient Randomized Trial to Evaluate Efficacy of Repurposed Medications, is an American study of repurposed drugs to treat COVID-19. The four drugs included in the study are ivermectin, fluvoxamine, fluticasone and montelukast.

It is part of the larger Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) initiative.

The study officially began on June 8, 2021, and is scheduled for completion in March 2024.1)

History

The study was first posted to ClinicalTrials.gov on May 13, 2021.2)

Participants

ACTIV-6 is being led by principal investigators Susanna Naggie and Adrian Hernandez at the Duke Clinical Research Institute.

Locations

Participating clinical trial sites include:

Funding

ACTIV-6 is funded by:3)

1) , 2)
Naggie, S., National Center for Advancing Translational Sciences (NCATS), & Vanderbilt University Medical Center. (2023, May 4). ACTIV-6: COVID-19 Outpatient Randomized Trial to Evaluate Efficacy of Repurposed Medications. ClinicalTrials.gov. https://web.archive.org/web/20230518153157/https://clinicaltrials.gov/ct2/show/NCT04885530
3)
Naggie, S., Boulware, D. R., Lindsell, C. J., Stewart, T. G., Slandzicki, A. J., Lim, S. C., Cohen, J., Kavtaradze, D., Amon, A. P., Gabriel, A., Gentile, N., Felker, G. M., Jayaweera, D., McCarthy, M. W., Sulkowski, M., Rothman, R. L., Wilson, S., DeLong, A., Remaly, A., & Wilder, R. (2023). Effect of Higher-Dose Ivermectin for 6 Days vs Placebo on Time to Sustained Recovery in Outpatients With COVID-19: A Randomized Clinical Trial. JAMA. https://doi.org/10.1001/jama.2023.1650